A citation-based method for searching scientific literature

Robert Clarke, John F Peden, Jemma C Hopewell, Theodosios Kyriakou, Anuj Goel, Simon C Heath, Sarah Parish, Simona Barlera, Maria Grazia Franzosi, Stephan Rust, Derrick Bennett, Angela Silveira, Anders Malarstig, Fiona R Green, Mark Lathrop, Bruna Gigante, Karin Leander, Ulf de Faire, Udo Seedorf, Anders Hamsten, Rory Collins, Hugh Watkins, Martin Farrall. N Engl J Med 2009
Times Cited: 850







List of co-cited articles
860 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
Sebhat Erqou, Stephen Kaptoge, Philip L Perry, Emanuele Di Angelantonio, Alexander Thompson, Ian R White, Santica M Marcovina, Rory Collins, Simon G Thompson, John Danesh. JAMA 2009
944
46

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
Pia R Kamstrup, Anne Tybjaerg-Hansen, Rolf Steffensen, Børge G Nordestgaard. JAMA 2009
728
41

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, Jean-Claude Tardif, Seth J Baum, Elizabeth Steinhagen-Thiessen, Michael D Shapiro, Erik S Stroes, Patrick M Moriarty, Børge G Nordestgaard,[...]. N Engl J Med 2020
242
41

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
36

Genetic associations with valvular calcification and aortic stenosis.
George Thanassoulis, Catherine Y Campbell, David S Owens, J Gustav Smith, Albert V Smith, Gina M Peloso, Kathleen F Kerr, Sonali Pechlivanis, Matthew J Budoff, Tamara B Harris,[...]. N Engl J Med 2013
537
31

Lipoprotein(a) as a cardiovascular risk factor: current status.
Børge G Nordestgaard, M John Chapman, Kausik Ray, Jan Borén, Felicita Andreotti, Gerald F Watts, Henry Ginsberg, Pierre Amarenco, Alberico Catapano, Olivier S Descamps,[...]. Eur Heart J 2010
30

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.
Don P Wilson, Terry A Jacobson, Peter H Jones, Marlys L Koschinsky, Catherine J McNeal, Børge G Nordestgaard, Carl E Orringer. J Clin Lipidol 2019
143
30

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Stephen Burgess, Brian A Ference, James R Staley, Daniel F Freitag, Amy M Mason, Sune F Nielsen, Peter Willeit, Robin Young, Praveen Surendran, Savita Karthikeyan,[...]. JAMA Cardiol 2018
219
29


Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
262
28


Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.
Guillaume Paré, Artuela Çaku, Matthew McQueen, Sonia S Anand, Enas Enas, Robert Clarke, Michael B Boffa, Marlys Koschinsky, Xingyu Wang, Salim Yusuf. Circulation 2019
95
26

Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.
Pia R Kamstrup, Anne Tybjærg-Hansen, Børge G Nordestgaard. J Am Coll Cardiol 2014
285
24

Elevated Lipoprotein(a) and Risk of Ischemic Stroke.
Anne Langsted, Børge G Nordestgaard, Pia R Kamstrup. J Am Coll Cardiol 2019
55
41

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera A Bittner, Michael Szarek, Philip E Aylward, Deepak L Bhatt, Rafael Diaz, Jay M Edelberg, Zlatko Fras, Shaun G Goodman, Sigrun Halvorsen, Corinne Hanotin,[...]. J Am Coll Cardiol 2020
134
23

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Nicholas J Viney, Julian C van Capelleveen, Richard S Geary, Shuting Xia, Joseph A Tami, Rosie Z Yu, Santica M Marcovina, Steven G Hughes, Mark J Graham, Rosanne M Crooke,[...]. Lancet 2016
403
23

Statin therapy increases lipoprotein(a) levels.
Sotirios Tsimikas, Philip L S M Gordts, Chelsea Nora, Calvin Yeang, Joseph L Witztum. Eur Heart J 2020
119
22


Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.
Salim S Virani, Ariel Brautbar, Brian C Davis, Vijay Nambi, Ron C Hoogeveen, A Richey Sharrett, Josef Coresh, Thomas H Mosley, Joel D Morrisett, Diane J Catellier,[...]. Circulation 2012
157
20

Lipoprotein (a) measurements for clinical application.
Santica M Marcovina, John J Albers. J Lipid Res 2016
139
20

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
Christian M Madsen, Pia R Kamstrup, Anne Langsted, Anette Varbo, Børge G Nordestgaard. Arterioscler Thromb Vasc Biol 2020
49
40

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.
Sotirios Tsimikas, Sergio Fazio, Keith C Ferdinand, Henry N Ginsberg, Marlys L Koschinsky, Santica M Marcovina, Patrick M Moriarty, Daniel J Rader, Alan T Remaley, Gissette Reyes-Soffer,[...]. J Am Coll Cardiol 2018
186
17

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
17

Lipoprotein(a): resurrected by genetics.
F Kronenberg, G Utermann. J Intern Med 2013
285
17

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Sotirios Tsimikas, Nicholas J Viney, Steven G Hughes, Walter Singleton, Mark J Graham, Brenda F Baker, Jennifer L Burkey, Qingqing Yang, Santica M Marcovina, Richard S Geary,[...]. Lancet 2015
298
17

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Peter Willeit, Paul M Ridker, Paul J Nestel, John Simes, Andrew M Tonkin, Terje R Pedersen, Gregory G Schwartz, Anders G Olsson, Helen M Colhoun, Florian Kronenberg,[...]. Lancet 2018
194
17


Structure, function, and genetics of lipoprotein (a).
Konrad Schmidt, Asma Noureen, Florian Kronenberg, Gerd Utermann. J Lipid Res 2016
168
16

Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.
Pia R Kamstrup, Marianne Benn, Anne Tybjaerg-Hansen, Børge G Nordestgaard. Circulation 2008
282
15

Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.
Pia R Kamstrup, Anne Tybjærg-Hansen, Børge G Nordestgaard. J Am Coll Cardiol 2013
140
14

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
893
14

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.
E Boerwinkle, C C Leffert, J Lin, C Lackner, G Chiesa, H H Hobbs. J Clin Invest 1992
790
14

High lipoprotein(a) and high risk of mortality.
Anne Langsted, Pia R Kamstrup, Børge G Nordestgaard. Eur Heart J 2019
79
17

Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.
Romain Capoulade, Kwan L Chan, Calvin Yeang, Patrick Mathieu, Yohan Bossé, Jean G Dumesnil, James W Tam, Koon K Teo, Ablajan Mahmut, Xiaohong Yang,[...]. J Am Coll Cardiol 2015
196
14



Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.
Weihua Guan, Jing Cao, Brian T Steffen, Wendy S Post, James H Stein, Mathew C Tattersall, Joel D Kaufman, Joseph P McConnell, Daniel M Hoefner, Russell Warnick,[...]. Arterioscler Thromb Vasc Biol 2015
82
15

Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.
Connor A Emdin, Amit V Khera, Pradeep Natarajan, Derek Klarin, Hong-Hee Won, Gina M Peloso, Nathan O Stitziel, Akihiro Nomura, Seyedeh M Zekavat, Alexander G Bick,[...]. J Am Coll Cardiol 2016
111
13

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes.
Daniel F Gudbjartsson, Gudmundur Thorgeirsson, Patrick Sulem, Anna Helgadottir, Arnaldur Gylfason, Jona Saemundsdottir, Eythor Bjornsson, Gudmundur L Norddahl, Aslaug Jonasdottir, Adalbjorg Jonasdottir,[...]. J Am Coll Cardiol 2019
52
25

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
237
13

LPA Gene, Ethnicity, and Cardiovascular Events.
Sang-Rok Lee, Anand Prasad, Yun-Seok Choi, Chao Xing, Paul Clopton, Joseph L Witztum, Sotirios Tsimikas. Circulation 2017
55
23


Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
12

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
12

A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.
K BERG. Acta Pathol Microbiol Scand 1963
12

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
12

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Eberhard Roeseler, Ulrich Julius, Franz Heigl, Ralf Spitthoever, Dennis Heutling, Paul Breitenberger, Josef Leebmann, Walter Lehmacher, Pia R Kamstrup, Børge G Nordestgaard,[...]. Arterioscler Thromb Vasc Biol 2016
110
12

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Michael Szarek, Vera A Bittner, Philip Aylward, Marie Baccara-Dinet, Deepak L Bhatt, Rafael Diaz, Zlatko Fras, Shaun G Goodman, Sigrun Halvorsen, Robert A Harrington,[...]. Eur Heart J 2020
41
29

A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms.
Salome Mack, Stefan Coassin, Rico Rueedi, Noha A Yousri, Ilkka Seppälä, Christian Gieger, Sebastian Schönherr, Lukas Forer, Gertraud Erhart, Pedro Marques-Vidal,[...]. J Lipid Res 2017
67
16

Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis.
Kang H Zheng, Sotirios Tsimikas, Tania Pawade, Jeffrey Kroon, William S A Jenkins, Mhairi K Doris, Audrey C White, Nyanza K L M Timmers, Jesper Hjortnaes, Maximillian A Rogers,[...]. J Am Coll Cardiol 2019
89
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.